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RNA viruses are sensed by RIG-I-like receptors
(RLRs), which signal through a mitochondria-associ-
ated adaptor molecule, MAVS, resulting in systemic
antiviral immune responses. Although RLR signaling
is essential for limiting RNA virus replication, it must
be stringently controlled to prevent damage from
inflammation. We demonstrate here that among
all tested UBX-domain-containing protein family
members, UBXN1 exhibits the strongest inhibitory
effect on RNA-virus-induced type I interferon
response. UBXN1 potently inhibits RLR- and
MAVS-induced, but not TLR3-, TLR4-, or DNA-
virus-induced innate immune responses. Depletion
of UBXN1 enhances virus-induced innate immune
responses, including those resulting from RNA
viruses such as vesicular stomatitis, Sendai, West
Nile, and dengue virus infection, repressing viral
replication. Following viral infection, UBXN1 is
induced, binds to MAVS, interferes with intracellular
MAVS oligomerization, and disrupts the MAVS/
TRAF3/TRAF6 signalosome. These findings under-
score a critical role of UBXN1 in the modulation of
a major antiviral signaling pathway.INTRODUCTION
The success of host defense against viral infections depends
upon the ability of the innate immune system to sense and
respond to invading pathogens. Intracellular detection of the viral
pathogen-associated molecular patterns (PAMPs) of viral RNA is
mediated predominantly by cytoplasmic sensors, the RIG-I-like
receptors (RLRs) RIG-I (also known as DDX58) and MDA5 (also
known as IFIH1) (Honda et al., 2006; Kawai and Akira, 2008;
Loo and Gale, 2011; Meylan and Tschopp, 2006; Onoguchi
et al., 2011; Wilkins and Gale, 2010; Yoneyama et al., 2004).
Upon engagement of viral RNA ligands, both RIG-I and MDA5Ctrigger a signaling cascade that culminates in the production of
cytokines and chemokines (Hornung et al., 2006; Kawai and
Akira, 2008; Meylan and Tschopp, 2006; Pichlmair et al., 2006;
Wilkins and Gale, 2010; Yoneyama et al., 2004). A central event
of RLR signaling is the rapid induction of type I interferons (IFNs)
to establish an antiviral state, via transcription factors such as
nuclear factor-kB (NF-kB), activator protein 1, and interferon
regulatory factor (IRF) (Hiscott et al., 2006; Maniatis et al.,
1998; Taniguchi et al., 2001). The synergistic effect of these
trans-activators on the promoters of type I interferon genes
induces an immediate-early interferon response, mainly IFN-b
and IFN-a1 (Honda et al., 2006). Secreted interferons then acti-
vate the Jak and STAT signaling to induce the expression of
hundreds of interferon-stimulated genes (ISGs) (Liu et al.,
2011; Matsumiya and Stafforini, 2010; Sadler and Williams,
2008; van Boxel-Dezaire et al., 2006).
Viral RNA binding enables the amino-terminal (N-terminal)
caspase-recruitment domain (CARD) of RLRs to interact with
the adaptor molecule MAVS (alternatively known as IPS-1/
CARDIF/VISA), a mitochondrial outer membrane protein (Kawai
et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al.,
2005). MAVS then recruits E3 ligases TRAF3 and TRAF6 via its
TRAF-interacting motif (TIM) (Paz et al., 2011; Xu et al., 2005),
leading to the activation of canonical IKKs and the IKK-related
kinases TBK1 and IKKε, and eventually to the production of
type I interferons and proinflammatory cytokines (Hornung
et al., 2006; Kumagai et al., 2008; Nakhaei et al., 2009; Pichlmair
et al., 2006). MAVS has been recently found to localize to perox-
isomes as well (Dixit et al., 2010). Upon viral infection, peroxi-
somal MAVS rapidly induces IFN-independent expression of
defense factors that provide short-term protection, while mito-
chondrial MAVS activates an IFN-dependent signaling pathway
with delayed kinetics, which amplifies and stabilizes the antiviral
response. Although activation of RLR signaling is necessary to
limit the spread of a broad spectrum of viral infections, it must
be tightly regulated to prevent excessive responses that may
result in deleterious effects on the host (Loo andGale, 2011;Mat-
sumiya and Stafforini, 2010). Recently, accumulating evidence
has suggested that aberrant IFN induction due to RLR signaling
is associated with autoimmune diseases (Loo and Gale, 2011;
Matsumiya and Stafforini, 2010). For example, genetic studiesell Reports 3, 1057–1070, April 25, 2013 ª2013 The Authors 1057
Figure 1. UBXN1 Negatively Regulates RNA-Virus-Induced Type I IFNs
(A) Schematic illustration of UBX family members for siRNA screening and quantification of ISRE promoter activity by dual-luciferase assay in HEK293 cells
transfected with scrambled (mock) or UBX-family-member-specific siRNAs and infected with VSV for 16 hr at a moi of 0.1 or 0.01.
(B) ELISA assay for IFN-b protein in VSV-infected HEK293 cells transfected with scrambled (mock) or UBXN1-specific shRNAs. Bottom: immunoblots of UBXN1
and actin from the whole-cell lysate.
(C) VSV titers from the cell culture medium of (B) at 24 hr after infection.
(D) Dual-luciferase assays of ISRE promoter activity in either VSV or SeV-infected HEK293 cells overexpressing Flag (vector) or Flag-tagged UBXN1, FAF1,
UBXD8, or UBXD3. Bottom: immunoblots of indicated proteins from the relevant whole-cell lysates.
(E) Microscopic images of VSV-GFP-infected HEK293 cells. Cells were transfected with indicated siRNA and 48 hr later infected with VSV (moi = 0.01) for 16 hr.
Images were acquired with a Zeiss fluorescence microscope (objective 53).
(legend continued on next page)
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have demonstrated that decreased or defective MDA5-medi-
ated IFN signaling is associated with resistance to type 1 dia-
betes (Loo and Gale, 2011). As a central molecule of the RLR
signaling, MAVS is regulated by host factors and is also the
target of viral proteins (Liu and Gu, 2011). The NLR family
member X1 (NLRX1) and poly(C)-binding protein 2 (PCBP2)
have been reported to be involved in the negative regulation of
MAVS-mediated signaling through different molecular mecha-
nisms (Moore et al., 2008; You et al., 2009). NLRX1 is a member
of nucleotide-binding domain and leucine-rich-repeat-contain-
ing (NLR) protein family, which is a ubiquitously expressed
protein that resides on the outer mitochondrial membrane where
MAVS is located. The amino terminus of NLRX1 contains a mito-
chondria-targeting sequence. In resting cells, NLRX1 is associ-
ated with MAVS, and expression of positive factors of RLR
signaling or IFN-b treatment is unable to alter the mRNA and
protein levels of NLRX1 (Moore et al., 2008). NLRX1 is therefore
thought of as an inhibitor of steady-state antiviral signaling rather
than as a negative-feedback inhibitor (Komuro et al., 2008;
Moore et al., 2008). PCBP2 belongs to the hnRNP E family of
RNA-binding proteins, which is retained mainly in the nuclei of
resting cells. In contrast to NLRX1, PCBP2 is highly inducible
by viral infection or IFN-a treatment. The induced PCBP2 trans-
locates to cytosol and binds to MAVS, which leads to the recruit-
ment of a HECT-domain-containing E3 ligase AIP4 to polyubiqui-
tinate and degradeMAVS (You et al., 2009). In addition to NLRX1
and PCBP2, other host factors are also involved in the temporal-
spatial regulation of MAVS-induced signaling complex (Komuro
et al., 2008), although themolecular mechanisms remain elusive.
The human genome encodes at least 13 ubiquitin-regulatory-X
(UBX)-domain-containing proteins, designated UBXN (Alexan-
dru et al., 2008). The UBX domain shares weak amino acid
homology with ubiquitin, and it adopts the same 3D fold as ubiq-
uitin (Alexandru et al., 2008; Schuberth and Buchberger, 2008).
One of the best understood UBXN proteins is p47, a cofactor
of the AAA ATPase p97 (Schuberth and Buchberger, 2008;
Yeung et al., 2008). p97 is highly conserved across species
and involved in diverse cellular processes, including ubiquitin-
dependent protein degradation, vesicle fusion, and cell-cycle
control (Chapman et al., 2011; Yeung et al., 2008). It has been
recently shown that several of the UBXN proteins bind to p97
and a large number of E3 ubiquitin ligases, suggesting that the
UBXN proteins participate in the global regulation of protein
turnover, most likely including proteins of immune function
(Alexandru et al., 2008; Besche et al., 2009; Chapman et al.,
2011; Schuberth and Buchberger, 2008; Yeung et al., 2008).
UBXN proteins may determine the substrate specificity of p97,
but for the majority of UBXN proteins the cellular function is
largely unknown. By using small interfering (si) RNA screening,
we demonstrate here that among all family members UBXN1
(also known as SAKS1/2B28) exhibits the strongest inhibitory
effect on RNA-virus-induced interferon promoter activity.
Further studies show that UBXN1 binds to MAVS, disrupting(F) Immunoblots of indicated proteins from the whole-cell lysates of (E).
(G) Quantification of secreted IFN-b concentrations fromHEK293 cells transfected
values in (A) and D) are expressed as fold induction over uninfected control.
Data represent the mean ± SEM (n = 3), *p < 0.05; **p < 0.01. See also Figure S1
Cthe MAVS-TRAF3/6 signaling complex and downstream antiviral
immune responses.
RESULTS
UBXN1 Is a Negative Regulator of RNA-Virus-Induced
Innate Immune Responses
To explore the potential role of UBXNproteins inmodulating anti-
viral response, we performed a limited small interfering RNA
(siRNA) screen in combination with a dual-luciferase reporter
assay, to identify either positive or negative regulators of type I
IFN signaling. All UBXN mRNA expression was readily detect-
able by quantitative RT-PCR, and, except for FAF2, all other
UBXNs were upregulated upon Sendai virus (SeV) infection of
HEK293 cells (Figure S1A). We then attempted to silence each
of theUBXNs using amix of three individual siRNA and examined
type I IFN response using a luciferase reporter. Results demon-
strate that of all tested family members silencing of UBXN1
(SAKS1/2B28) led to the greatest induction of ISRE reporter
luciferase activity after RNA virus infection, including vesicular
stomatitis virus (VSV)-GFP and SeV, suggesting that UBXN1
may be a negative regulator of virus-induced IFN signaling (Fig-
ure 1A). To confirm this, we generated a cell line expressing
UBXN1-small hairpin RNA (shRNA) andmeasured IFN-b produc-
tion in UBXN1-silenced cells infected with VSV-GFP. In agree-
ment with the siRNA screening findings, these cells secreted
greater amounts of IFN-b protein than scrambled shRNA-treated
cells (Figure 1B). Consequently, VSV titers were decreased
6-fold when UBXN1 was silenced (Figure 1C). These data
suggest that UBXN1 is potentially involved in IFN regulation.
This was further strengthened by the observations that UBXN1
protein expression was induced by not only viral infection but
also IFN-b (Figure S1B).
Based on their protein domain composition, the human
UBXNs are subclassified into two main groups: the UBA-UBX
proteins and UBX-only proteins (Alexandru et al., 2008). To vali-
date our siRNA screening results, we assessed the effect of
UBXN overexpression on virus-induced ISRE promoter activa-
tion. We included two of the UBA-UBX proteins FAF1 and
UBXD8, and one of the UBX-only proteins, UBXD3. Consistent
with siRNA results, overexpression of UBXN1 dramatically
repressed VSV-GFP-induced ISRE activation compared to the
vector control, while overexpression of FAF1 and UBXD8 had
no effect on ISRE activity. In agreement with the siRNA screening
results, UBXD3 also demonstrated an inhibitory effect on VSV-
GFP or SV-induced ISRE promoter activation, albeit to a much
lesser extent than UBXN1 (Figure 1D). We next assessed the
relative importance of UBXN1, UBXD3, and a previously estab-
lished negative regulator NLRX1 (Moore et al., 2008), in control-
ling VSV-GFP infection by siRNA knockdown in parallel.
Silencing either UBXN1 or NLRX1, but not UBXD3 greatly
reduced VSV replication in terms of GFP intensity (Figure 1E)
and amount of VSV glycoprotein (VSV-G), as assessed bywith indicated siRNA and subsequently infectedwith VSV by ELISA. Luciferase
.
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Figure 2. UBXN1 Inhibits SV-Induced IFN
Signaling
(A) Quantification of ISRE, IFNb, and NFkB
promoter activities in HEK293 cells transfected
with either empty vector or increasing amounts of
Myc-UBXN1 plasmid 16 hr after SeV infection.
(B) Quantification of IFN-a4 promoter activity of
HEK293 cells transfected with either empty vector
or increasing amounts of Myc-UBXN1 plasmid
and a constant amount of IRF7 plasmid 16 hr after
SV infection.
(C) ELISA of IFN-b secreted from HEK293 cells
transfected with either control vector or Myc-
UBXN1 expression plasmid 16 hr after SV
infection.
Shown are mean ± SEM (n = 3). *p < 0.05.immunoblotting (Figure 1F). Type I IFN response was increased
in UBXN1 and NLRX1, but only modestly in UBXD3 knockdown
cells (Figure 1G). In addition, SV-induced ISRE, NF-kB-, IFNb-,
and IFNa4-promoter activation were also inhibited by UBXN1
in a dose-dependent manner (Figures 2A and 2B). In parallel,
SV-induced IFN-b protein production was strikingly decreased
when UBXN1 was overexpressed (Figure 2C). Taken together,
these results demonstrate that UBXN1 inhibits virus-induced
IFN and NF-kB signaling.
UBXN1 Negatively Regulates West Nile Virus- and
Dengue Virus-Induced Innate Immune Response
West Nile virus (WNV) is an enveloped, single-stranded, positive-
sense RNA virus of the Flaviviridae family and is endemic in the
Middle East and parts of North America (Fredericksen et al.,
2008; Suthar et al., 2010). There have been over 1,400 lethal
human cases of WNV since 1999 and over 240 deaths in 2012
alone in the United States. To expand our findings, we employed
WNV to test whether endogenous UBXN1 suppresses WNV-
induced host antiviral responses. We first generated a stable
UBXN1-silenced A549 cell line by using plasmid-mediated
shRNA interference. These UBXN1-silenced A549 cells pro-
duced more IFN-b protein and mRNA than that of control
shRNA-treated cells, which is concomitant with decreased intra-
cellular viral replication and yield of extracellular infectious viral
particles (Figures 3A–3D and S2A–S2C). In parallel, IFN-stimu-
lated gene (ISG) expression in response to WNV infection was
also monitored by immunoblotting assays. Phosphorylation of
STAT1 and the expression levels of ISG15 and RIG-I were
enhanced inUBXN1-silenced cells, as compared to control cells
(Figure 3E). Moreover, the expression levels of NF-kB-respon-
sive genes, TNFa and IL6, were elevated in UBXN1-silenced
cells (Figure S2C). In line with these results, siRNA directed
against human and mouse UBXN1 resulted in similar effects in
A549 cells and mouse primary bone-marrow-derived macro-
phages, respectively (Figures 3F, 3G, and S2D).1060 Cell Reports 3, 1057–1070, April 25, 2013 ª2013 The AuthorsWe further extended our study to
another medically important flavivirus,
type II dengue virus (DENV), which is
endemic throughout the tropics and
South Asia (Loo et al., 2008). Wemeasured protein production of IFN-b, the NF-kB-responsive
proinflammatory cytokine tumor necrosis factor a (TNF-a), and
DENV replication, as measured by real-time RT-PCR and plaque
assay in UBXN1-silenced cells. As expected, these cells ex-
hibited enhanced protein production of IFN-b and TNF-a and
reduced DENV replication, compared to control siRNA-treated
cells (Figure S3). Thus, we show that UBXN1 plays an important
role in controlling the innate antiviral response to virus infection.
UBXN1 Blocks RLR-Dependent Antiviral Signaling
Given that WNV, DENV, VSV, and SV are potent agonists of the
RLR signaling pathway (Cui et al., 2010; Kato et al., 2008; Loo
et al., 2008; Saha et al., 2006), we next evaluated the impact
of UBXN1 overexpression on ISRE promoter activity using
synthetic analogs of viral RNAs, 50-triphosphate RNA (a potent
stimulator of RIG-I) (Hornung et al., 2006; Pichlmair et al.,
2006), and high-molecular-weight poly(I:C) (an agonist of
MDA5 [Kato et al., 2008]). UBXN1 significantly inhibited RLR-
agonist-induced ISRE promoter activation in a dose-dependent
manner (Figure 4A). To confirm the inhibitory role of UBXN1 in the
RLR signaling pathway, we ectopically expressed the cytosolic
receptor MDA5, the constitutively active form of RIG-I (DRIG-I),
or the adaptor molecule MAVS along with increasing amounts
of UBXN1. DRIG-I-, MDA5-, and MAVS-induced ISRE, NF-kB,
and IFNb promoter activation were significantly reduced by
UBXN1 in a dose-dependent manner (Figures 4B–4D). The
UBXN1-mediated regulation of the IFN pathway was also
confirmed by ELISA, demonstrating that UBXN1 inhibited
DRIG-I-, MDA5-, and MAVS-induced IFN-b protein produc-
tion (Figure 4E). Furthermore, UBXN1 significantly inhibited
DRIG-I-, MDA5-, and MAVS-mediated IRF3 phosphorylation, a
hallmark of IFN activation (Figure 4F). These data collectively
demonstrate that UBXN1 is a potent inhibitor of RLR signaling
and inhibits the IFN antiviral response downstream of MAVS.
To determine whether the immunoregulatory function of UBXN1
is conserved across species, we generated an expression
Figure 3. RNA Interference of UBXN1 Results in Enhanced Antiviral Response
(A and B) Quantification of (A) IFNbmRNA levels by Taqman quantitative real-time PCR (q-PCR) normalized to b-actin, and (B) secreted IFN-b levels by ELISA in
A549 cells stably expressing either scrambled shRNA (control) or UBXN1-targeting shRNA, after WNV infection (moi = 1).
(C and D) Quantification of (C) intracellular WNV loads by q-PCR or (D) infectious viral particles in the culture medium by plaque assay from A549 cells stably
expressing either scrambled shRNA (control) or UBXN1-targeting shRNA.
(E) Immunoblots of viral proteins (NS3, NS2B), select ISGs, and UBXN1, using specific antibodies in A549 cells stably expressing either scrambled shRNA
(control) or UBXN1-targeting shRNA at various times (hr) after WNV infection.
(F and G) Quantification of indicated cytokine levels by ELISA, and WNV loads by q-PCR from (F) A549 cells or (G) bone-marrow-derived mouse macrophages in
the presence of control or UBXN1-targeting siRNA. The immunoblots indicate the knockdown efficiency.
Data represent mean ± SEM (n = 3). *p < 0.05, **p < 0.01. See also Figures S2 and S3.
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Figure 4. UBXN1 Blocks RLR Signaling
(A) Quantification of ISRE promoter activity of
A549 cells transfected with either an empty vector
or increasing amounts of UBXN1 plasmid and
treated with 50-triphosphate RNA or polyI:C. Data
are expressed as fold induction over nontreated
cells.
(B–D) Quantification of (B) ISRE-, (C) NFkB-, and
(D) IFNb-promoter activity of HEK293 cells ex-
pressing GFP-DRIG-I, GFP-MDA5, or GFP-MAVS,
together with increasing amounts of Myc-UBXN1.
Data are presented as fold induction over empty
vector.
(E) ELISA of IFN-b secreted from HEK293 cells
transfected with indicated expression plasmids
and either an empty vector or Myc-UBXN1
expression plasmid.
(F) Immunoblotting analyses of whole-cell lysates
of HEK293 cells transfected with plasmids as
described in (E).
Data represent mean ± SEM (n = 3). *p < 0.05;
**p < 0.01. See also Figures S4 and S5.plasmid encoding the mouse Ubxn1 cDNA. The amino acid
sequences of UBXN1 are highly homologous between human,
mouse, and rat (Ishibashi et al., 2005). Both human and mouse
UBXN1 proteins are 297 amino acids and share 91.3%
homology, implying conserved function (Figures S4A and S4B).
Overexpression of mouse Ubxn1 markedly blocked DRIG-I-,
MDA5-, andMAVS-induced ISRE and IFN-b promoter activation,
suggesting that its function as a negative regulator of RLR
signaling is evolutionarily conserved across species (Figures
S4C–S4E).
MAVS Is the Target of UBXN1
To identify the potential target of UBXN1 in RLR signaling, we
expressed MAVS, the noncanonical kinase IKKε-, TBK1, or the
constitutively active form of IRF3 [IRF3(5D)], along with in-
creasing amounts of UBXN1. UBXN1 strongly inhibited the
type I IFN production induced by MAVS but not by TBK1, IKKε,
or IRF3 (5D) (Figure 5A), though UBXN1 modestly inhibited
TBK1- or IKKε-mediated ISRE promoter activity (Figure S5I).
Similar results were also observed with mouse Ubxn1 (Figures1062 Cell Reports 3, 1057–1070, April 25, 2013 ª2013 The AuthorsS4F–S4H). These data therefore suggest
that UBXN1 targets the MAVS signaling
complex (Figure 5B). Consistent with
this, UBXN1 interacted only with MAVS,
but not with other known components of
the RLR signaling pathway, including
RIG-I, MDA5, TBK1, IKKε, IRF3, or IRF7,
indicating the specificity of UBXN1-
MAVS physical and functional interac-
tions (Figures 5C and 5D). Given that
MAVS contains TRAF-interacting motifs
that allow MAVS to recruit TRAF3 and
TRAF6 and assemble the MAVS signaling
complex (Paz et al., 2011; Saha et al.,
2006; Xu et al., 2005), we investigated
whether UBXN1 can interfere with theassembly of MAVS/TRAF3/TRAF6 signalosome. Competitive
coimmunoprecipitation assays demonstrate that both MAVS-
TRAF3 and MAVS-TRAF6 interaction were disrupted by
UBXN1 in a dose-dependent manner, and there was no detect-
able interaction of UBXN1 with either TRAF3 or TRAF6 (Fig-
ure 5E). Overexpression of UBXN1 also disrupted endogenous
MAVS-TRAF6 interaction in the presence or absence of VSV-
GFP infection (Figure 5F). In contrast, depletion of UBXN1 by
siRNA enhanced endogenous MAVS-TRAF6 interaction follow-
ing VSV-GFP infection (Figure 5G). Furthermore, MAVS-induced
activation of ISRE, NF-kB, RANTES, and IFNa1 promoters
were enhanced in UBXN1-silenced cells (Figure 5H). To assess
the relative importance of UBXN1 on MAVS regulation, we
compared it with a well-known MAVS inhibitor, NLRX1. Overex-
pression of UBXN1 resulted in a similar fold inhibition on
MAVS-induced type I IFN response as NLRX1 (Figure S5A).
We next asked if UBXN1 interferes with TLR-mediated or DNA-
virus-induced type I IFN response. Overexpression of UBXN1
had no effect on TLR3-mediated, TLR4-mediated, or herpes-
simplex-virus (HSV)-induced IFNb promoter activation (Figures
S5B–S5D). Taken together, these observations strongly indicate
that UBXN1 specifically interferes with MAVS function.
UBXN1 Targets a TRAF3/6-Binding Site of MAVS
To characterize the UBXN1-binding motif of MAVS, we gener-
ated a series of MAVS deletion constructs. We transfected cells
with plasmids encoding each MAVS mutant, along with an ex-
pression plasmid of UBXN1, and assessed binding to UBXN1
by coimmunoprecipitation. UBXN1 bound strongly to full-length
and aa 1–467 MAVS, weakly to the C terminus containing the
transmembrane domain (D420 and D440), but failed to bind to
other C-terminally truncated forms of MAVS (1–400, 1–420,
and 1–440, Figure 6A, left panel). These results suggest that
UBXN1 predominantly binds to the amino acid spanning 440–
467 of MAVS. Indeed, this region alone was sufficient for
UBXN1 binding (Figure 6A, right panel). MAVS with the trans-
membrane domain (TM; required for MAVS subcellular localiza-
tion; Figure 6A) (Seth et al., 2005) and CARD domain only
(MAVSD) was able to bind UBXN1, but to a much less extent
than full-length protein. Substitution of the TMdomain of MAVSD
with the TM domain of a mitochondrial membrane protein
OMP25 (MAVS1–100mimic; Dixit et al., 2010) completely abol-
ished UBXN1 binding (Figure 6B, left panel). However, substitu-
tion of the TM domain of full-length MAVS with the TM domain of
a mitochondrial membrane protein OMP25 (MAVS1–500mimic)
did not appreciably reduce UBXN1 binding (Figure 6B, right
panel). Taken together, these results indicate that the residues
440–467 of MAVS are necessary and sufficient for strong
UBXN1 binding. Interestingly, it has been previously demon-
strated that MAVS has two TRAF3-binding sites (aa 143–147
and 455–460) (Xu et al., 2005; Paz et al., 2011) and two
TRAF6-binding sites (aa 153–158 and 455–460) (Xu et al.,
2005; Saha et al., 2006). Thus, our results suggest that UBXN1
specifically competes for the TRAF3/6-binding site (aa 455–
460) of MAVS to block TRAF3/6 recruitment to MAVS. Consis-
tent with this notion, UBXN1 significantly repressed type IFN
production induced only by full-length and 1–500mimic MAVS
that contains the TRAF3/6-binding site, but not by 1–100mimic,
1–300mimic, or MAVSD100-452 (Figures 6C and S6A).
TheNTerminus Containing theUBADomain of UBXN1 Is
Required and Sufficient for MAVS Inhibition
We next asked which domain of UBXN1 binds to and inhibits
MAVS function. UBXN1 contains an N-terminal UBA domain,
a coil-coiled (CC) domain, and a C-terminal UBX domain. To
identify the MAVS-binding motif within UBXN1, we generated
a series of UBXN1 deletion or mutation constructs tagged with
GFP orMyc. Surprisingly, MAVS interacted with all the functional
domains of UBXN1 (Figure S6B). A similar interaction mode was
also observed between NLRC5 and IKKb, in which NLRC5 nega-
tively regulates IKKa/b-mediated NF-kB activation (Cui et al.,
2010). As it appears that residues 438–467 mediate MAVS
binding to UBXN1, we hypothesize that the UBXN1 domain
that binds to MAVS 438–467 may be of prime physiological
significance. Only the N terminus (1–86) and the DCC (aa 1–86
joined with 173-end) retained comparable MAVS438-467-
binding as full-length UBXN1 (Figure 6D). Consistent with these
findings, only the N terminus and the DCC forms of UBXN1 re-Ctained the same fold-inhibitory effect on MAVS-induced type I
IFN production as full-length UBXN1 (Figure 6E). The C terminus
(173-end) and UBX domain (211-end) of UBXN1 were dispens-
able for its MAVS-inhibiting function. In addition, deletion of the
UBX domain did not affect the inhibitory activity of UBXN1 on
both MAVS- and SV-induced IFNb promoter activation, indi-
cating that the UBX domain is not essential (Figures S6C and
S6D). Although theminimal UBA domain (1–42) alonewas unable
to inhibit MAVS function, the UBA-truncated form(DUBA) and
the UBA domain mutant (AAA) also failed to inhibit MAVS func-
tion (Figures 6E, S6C, and S6D). Taken together, these results
indicate (1) the UBA domain (1–42) is necessary, but not suffi-
cient, (2) the N terminus (1–86) alone is sufficient, and that (3)
physical binding to MAVS is necessary, but not sufficient, for
the observed inhibitory effect of UBXN1 on MAVS signaling.
Endogenous UBXN1 Colocalizes with MAVS after Viral
Infection
Our previous data demonstrated that UBXN1 interacts with
MAVS under the experimental condition of transient transfec-
tion and overexpression. To test whether endogenous UBXN1
interacts with MAVS after RNA virus infection, we infected
A549 cells with SV at a high multiplicity of infection (moi). In-
fected cells were collected at varying time points after infection,
lysed, and subjected to coimmunoprecipitation. Twenty-four
hours after SV infection, endogenous MAVS coimmunoprecipi-
tated with endogenous UBXN1, which itself was induced
several-fold (Figure 7A). This result is supported by the obser-
vation that after SV infection UBXN1 and MAVS colocalized
in primary human foreskin fibroblast cells (HFFs) (Figure 7B)
and mouse embryonic cells (MEFs) (Figure 7C), as assessed
by confocal immunofluorescence microscopy. In parallel, the
negative regulatory effects of Ubxn1 in primary MEFs were
also evaluated after WNV infection. Specific silencing of endog-
enous Ubxn1 expression resulted in upregulation of Ifnb
expression, concomitant with decreased WNV replication (Fig-
ure 7D). Taken together, these findings suggest that at a rela-
tively late phase after RNA virus infection endogenous UBXN1
is induced and interacts with MAVS, curtailing the antiviral
immune response.
UBXN1 Disrupts MAVS-MAVS Interaction
Upon virus infection MAVS is known to oligomerize and form
structures that resemble prion fibrils inside cells (Hou et al.,
2011). We wished to see if UBXN1 disrupted MAVS-MAVS inter-
actions. To do so, we constructed four N- and C-terminal fusions
of MAVS with enhanced yellow fluorescent protein (eYFP) and
cyan fluorescent protein (CFP). These constructs were overex-
pressed by transient transfection in 293T cells, which were
then analyzed by flow cytometry for fluorescence resonance
energy transfer (FRET). MAVS FRETed with itself (Figure S7A),
and the FRET signal was reduced in the presence of Myc-
UBXN1 as competitor but not by HIV Gag (Figures S7B and
S7C). MAVS-MAVS FRET signal was also reduced in the
presence of Flag-MAVS (Figure S7D). As a known positive
control, HIV Gag strongly FRETed with itself (Figure S7E), which
was reduced by excess competitor Gag (Figure S7F) but not
by Myc-UBXN1 or Flag-MAVS (Figures S7G and S7H). Theseell Reports 3, 1057–1070, April 25, 2013 ª2013 The Authors 1063
Figure 5. UBXN1 Blocks MAVS Function
(A) Quantification of type I IFN, using a 2fGTH cell line stably expressing ISRE-Luc, from the cell culturemedium of HEK293 cells expressing increasing amounts of
Myc-UBXN1 together with GFP-tagged MAVS, TBK1, IKK, or Flag-IRF3(5D), respectively.
(B) Schematic graph showing the potential target of UBXN1 in the RLR signaling pathway.
(legend continued on next page)
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results, taken together, suggest that UBXN1 is able to disrupt
MAVS-MAVS interaction in intact, living cells.
UBXN1was recently demonstrated to potentially participate in
p97-mediated protein turnover and to modify protein function by
binding to polyubiquitin chains (Alexandru et al., 2008; Besche
et al., 2009). We tested if overexpression of UBXN1 facilitated
MAVS degradation. Total MAVS protein levels remained largely
unchanged when UBXN1 was overexpressed in the absence
or presence of the proteasome inhibitors Bortezomib and
MG132 (Figure S8). This suggests that UBXN1 does not mediate
its inhibitory activity by degrading MAVS or otherwise targeting it
to the proteasome.
DISCUSSION
The UBXN family members are believed to participate in multiple
biological processes. However, the function of most of the family
members still remains to be explored. In particular, the involve-
ment of any UBXN genes in the innate immune system has not
yet been reported. In this study, we demonstrated by several
lines of evidence that UBXN1 functions as a negative regulator
of RNA-virus-induced host antiviral response. First, depletion
of endogenous UBXN1 expression by small RNA interference
enhances RNA-virus-induced IFNb promoter activation and
IFN-b protein secretion. Second, overexpression of UBXN1
strikingly inhibits either RNA-virus-induced or positive factors
of RLR-signaling-induced IFN-b production andNF-kBpromoter
activation. Third, knockdown of UBXN1 by RNA interference
promotes West-Nile- and Dengue-virus-induced IFN-b and
proinflammatory cytokine production and repressed viral repli-
cation. Fourth, overexpression of UBXN1 disrupts the assembly
of MAVS/TRAF3/TRAF6 signaling complex. Fifth, SeV infection
induces endogenous UBXN1-MAVS interaction and colocaliza-
tion. Sixth, UBXN1 disruptsMAVS-MAVS interaction inside cells.
Based on its protein domain composition, UBXN1 is consid-
ered as one of the UBA-UBX-containing subfamily of human
UBXNs. The UBXNs are generally believed to be the adaptor
molecules of p97, an AAA ATPase that is highly conserved
across species and involved in diverse cellular processes, in-
cluding ubiquitin-dependent protein degradation, vesicle fusion,
and the cell cycle (Alexandru et al., 2008; Chapman et al., 2011;
Schuberth and Buchberger, 2008; Yeung et al., 2008). UBXN1
has been recently shown to bind p97 and polyubiquitin, posi-
tively (Alexandru et al., 2008; Besche et al., 2009; Ishibashi
et al., 2005) or negatively (LaLonde and Bretscher, 2011), regu-
lating protein degradation. However, our data indicate that(C) Coimmunoprecipitation (coIP) of MAVS and UBXN1 fromHEK293 cells expres
by immunoblotting (IB). WCE, whole-cell extract.
(D) CoIP of MAVS and UBXN1 from HEK293 cells expressing Myc-UBXN1 and G
blotting (IB) using a Myc or GFP antibody.
(E) Displacement of TRAF fromMAVS by UBXN1 in a dose-dependent manner. C
increasing amounts of UBXN1-Myc, using either an Flag or GFP antibody.
(F) CoIP of endogenous MAVS and TRAF6 from HEK293 cells expressing Myc
noblotting (IB) using a mouse MAVS or TRAF6 antibody.
(G) CoIP of MAVS and TRAF6 from HEK293 cells transfected with a scrambled o
(H) Quantification of ISRE, NFkB, RANTES, and IFNa1 promoter activity by dual-lu
HEK293 cells transfected with either empty vector or GFP-MAVS plasmid (MAVS
Data represent mean ± SEM (n = 3). **p < 0.01. See also Figure S5.
CMAVS protein levels are largely unaffected in the presence of
increasing amounts of exogenous UBXN1. Furthermore, the
C-terminal UBX domain of UBXN1, which mediates the binding
and recruitment of p97 to a target substrate, is dispensable for
its inhibitory effect on MAVS function, suggesting that the regu-
latory effect of UBXN1 on MAVS is independent of p97 action.
Last, of the UBA-UBX proteins, the regulatory effect of UBXN1
on MAVS is unique and specific because either knockdown or
overexpression of the other two UBA-UBX proteins, FAF1 and
FAF2, shows no substantial impact on either VSV- or SV-induced
IFN response.
How does UBXN1 regulate MAVS? As a central adaptor of
RLRs, MAVS signaling is held in check by negative regulators
to prevent excessive immune response. NLRX1, PCBP2, and
RNF5 are recently identified cellular factors that limit MAVS
signaling through distinct molecular mechanisms (Moore et al.,
2008; You et al., 2009; Zhong et al., 2010). NLRX1 resides on
the outer mitochondrial membrane where MAVS is located and
acts as an inhibitor of steady-state antiviral signaling (Moore
et al., 2008). In contrast, PCBP2, which is predominantly local-
ized in the nuclei of unstimulated cells, translocates to the
cytosol and binds to MAVS after viral infection, leading to the
recruitment of the E3 ubiquitin ligase AIP4 and subsequent pro-
teasomal degradation of MAVS (You et al., 2009). RNF5 is
another ligase that targets MAVS for K48-linked ubiquitination
and proteasomal degradation (Zhong et al., 2010). Surprisingly,
IKKε, a protein kinase that phosphorylates IRF3 to activate IFN
transcription, was recently shown to bind to a TRAF3-binding
site (aa 468–540) in MAVS via K63 ubiquitination, resulting in
downregulation of the IFN response (Paz et al., 2009, 2011). In
contrast, Castanier et al. recently showed that TRIM25-mediated
proteasomal degradation of MAVS via lysine 7 and 10 after RLR
activation is required for release of TBK1 into cytosol, allowing
IRF3 phosphorylation and type I IFN expression (Castanier
et al., 2012). Our results show that full-length UBXN1 primarily
blocks a TRAF3/6-binding site (aa 450–480) that is critical for
MAVS-mediated type IFN induction (Paz et al., 2011), suggesting
that UBXN1 simply serves as a dominant-negative binder of
MAVS. Except for a putative role in ERAD via p97, UBXN1 also
likely blocks the function of its target proteins by binding to their
polyubiquitin chains (McNeill et al., 2004; Wu-Baer et al., 2010).
Of note, the UBA domain of UBXN1 binds K6-linked polyubiqui-
tin chains conjugated to BRCA1 and blocks its E3 ligase activity
(Wu-Baer et al., 2010). Our data, however, show that replace-
ment of the unique lysine residuewithin theUBXN1-bindingmotif
(438–467) with an arginine (K461R) does not affect MAVS activitysing Myc-UBXN1 andGFP-MAVS using anMycmonoclonal antibody, followed
FP-tagged proteins using a GFP monoclonal antibody, followed by immuno-
oIP was performed with HEK293 cells expressing MAVS-GFP, Flag-TRAF, and
or Myc-UBXN1 using a rabbit MAVS polyclonal antibody, followed by immu-
r UBXN1 siRNA and immunoblotting (IB) as in (F).
ciferase reporter assay in scrambled (control) shRNA or UBXN1 shRNA-treated
). Luciferase values in are expressed as fold induction over vector control.
ell Reports 3, 1057–1070, April 25, 2013 ª2013 The Authors 1065
Figure 6. Characterization of MAVS and
UBXN1 Mutual Binding Motifs
(A) Interaction of MAVS truncation mutants with
full-length UBXN1. Left panel: schematic of MAVS
deletion mutants. Middle panel: coimmunopreci-
pitation (IP) of MAVS and UBXN1 from HEK293
cells expressing GFP-UBXN1 together with Myc-
tagged MAVS variants using a Myc monoclonal
antibody, followed by immunoblotting (IB) using
a Myc or GFP antibody. Right panel: binding
of UBXN1 to MAVS438-467. WCE, whole-cell
extract.
(B) CoIP of MAVS truncation mutants with a mimic
transmembrane domain with full-length UBXN1
as in (A).
(C) Quantification of type I IFN, using a 2fGTH cell
line stably expressing ISRE-Luc, in the cell culture
medium of HEK293 cells expressing increasing
amounts of Myc-UBXN1 together with Flag-
tagged MAVS full-length, MAVSD, or MAVS-
mimic. Immunoblots under the chart indicate the
intracellular Myc-UBXN1 expression levels.
(D) Interaction of UBXN1 deletion mutants with
MAVS438-467. Left panel: schematic diagram
of UBXN1 deletion mutants. Right panel: coIP
of MAVS and UBXN1 from HEK293 cells ex-
pressing GFP-MAVS438-467 and Flag-tagged
UBXN1 mutants using anti-Flag agarose beads,
followed by IB using a Flag or GFP antibody.
(E) Quantification of type I IFNs from the culture
medium of HEK293 cells expressing increasing
amounts of Myc-tagged UBXN1 truncates and
GFP-MAVS, as described in (C). Immunoblots
under the chart indicate the intracellular Myc-
UBXN1and GFP-MAVS expression levels.
Data in (E) and (G) represent mean ± SEM (n = 3).
**p < 0.01. See also Figure S6.or the inhibitory capacity of UBXN1 on MAVS signaling (data not
shown). These results suggest that the MAVS-inhibiting activity
of UBXN1 is likely independent of ubiquitination. Surprisingly1066 Cell Reports 3, 1057–1070, April 25, 2013 ª2013 The Authorsall of the UBXN1 functional domains
when overexpressed are capable of
binding to the full-length MAVS, only the
UBA-containing N terminus (aa 1–86) of
UBXN1 binds to MAVS 438–467 and is
also necessary and sufficient for its
MAVS-inhibitory function. This suggests
that an additional cellular factor(s) that
specifically interacts with the N terminus
of UBXN1 among other possibilities may
be required. The fact that MAVS-UBXN1
did not FRET with each other (data not
shown) suggests a cofactor may be
involved in the observed interaction.
Importantly, the presence of excess
UBXN1 does not result in MAVS degrada-
tion; thus, it is more likely that UBXN1
acts as a steric ‘‘antagonist’’ of MAVS.
In addition to localization on mito-
chondrial outer membranes, MAVS hasrecently been shown to reside on peroxisomal membranes,
where it induces swift IFN-independent expression of antiviral
factors upon virus infection (Dixit et al., 2010). This rapid-early
Figure 7. SV Infection Induces Endogenous UBXN1 and MAVS Interaction and Colocalization
(A) CoIP of MAVS and UBXN1 from A549 cells after SV infection using a MAVS antibody pull-down and IgGs as a control, followed by immunoblotting (IB). WCE,
whole-cell extract.
(B and C) Confocal immunofluorescence microscopy of UBXN1 and MAVS after SeV infection in primary (B) HFFs and (C) MEFs. UBXN1/MAVS/nucleus was
stained with secondary antibodies conjugated with Alexa Fluor 546/488 and TO-PRO-3, respectively. Images were acquired using a Zeiss LSM 510 Meta
(objective 633). Arrows indicate representative colocalization.
(D) Quantification of IFNbmRNA levels and intracellularWNV load by Taqman quantitative real-time PCR (q-PCR), normalized to b-actin, inMEFs transfectedwith
scramble (control) or Ubxn1-targeting siRNA and infected with WNV (moi = 1). Data represent mean ± SEM (n=3). **p < 0.05.
See also Figure S6.
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response may provide a critical short-term protection before the
initiation of mitochondrial MAVS signaling, which activates,
amplifies, and stabilizes a state of IFN-dependent antiviral immu-
nity. Our results suggest that UBXN1 is unlikely to be an early-
stage inhibitor of peroxisomal MAVS-dependent signaling but
rather UBXN1 modulates the sustained mitochondrial MAVS-
dependent antiviral response.
In conclusion, UBXN1 is induced and recruited to MAVS after
virus infection, serving as a brake to prevent excessive RLR
signaling, most likely at a late stage of infection. This mode of
action may help avoid cell death and tissue destruction due to
hyperimmune responses, without compromising necessary anti-
viral immunity. In this sense, UBXN1 may be an ideal target for
the development of novel therapies for inflammatory and autoim-
mune diseases that have been associated with aberrant or
protracted RLR signaling (Loo and Gale, 2011). In addition, our
findings regarding UBXN1 offer insights into the molecular func-
tions of this highly conserved gene family.
EXPERIMENTAL PROCEDURES
RNA Interference
For siRNA screening, 1 3 105 HEK293 were plated into polyornithine-coated
24-well cell culture plates. Sixteen hours later, cells were transfected with
40 pmol of siRNA mix directed against human UBXNs (three 27-mer siRNAs
from Origene) or NLRX1 (#EHU111901, Sigma-Aldrich) using Lipofectamine
2000 (Invitrogen). Cells were transfected again with luciferase reporter
plasmids (100 ng ISRE-luc and 50 ng pRL-TK per well) 36 hr after siRNA trans-
fection. Cells were infected with GFP-vesicular stomatitis virus 48 hr after
siRNA transfection (Zhao et al., 2007). Cells were washed gently with PBS
and lysed for Dual Glow Luciferase assay following the manufacturer’s
instructions (Promega) 16 hr after infection. For siRNA knockdown in bone-
marrow-derived mouse macrophages or A549 cells, 1–2 3 106 cells were
transfected by electroporation (Lonza) with 100 pmol of mouse Ubxn1 siRNA
(Dharmacon #J-051867-09 and J-051867-10) or human UBXN1 siRNA (Ori-
gene #SR309485, vial number 451335 and 451337), respectively. Cells were
ready for other manipulations (virus infection or luciferase reporter assay)
48 hr after transfection.
For generating stable UBXN1 knockdown cell lines, a UBXN1-specific
shRNA (#TF306979 OriGene Technologies) was retrovirally transfected
(Zhao et al., 2007) into HEK293 and A549 cells. Stably transduced bulk
cultures were selected in media containing puromycin (2 mg/ml; Sigma), and
individual cell clones were isolated and confirmed by immunoblotting.
Analysis of Protein-Protein Interactions
HEK293 cells were transfected with expression plasmids using Lipofect-
amine 2000. Whole-cell extracts (300 mg) were prepared from transfected
cells and were incubated for 1 hr at 4C with 1 mg of mouse monoclonal
Myc (Sigma-Aldrich), GFP (Roche), or Flag (Sigma-Aldrich) antibody cross-
linked to protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology).
For coimmunoprecipitation of endogenous proteins, A549 cells were infected
with SeV at a concentration of 80 hemagglutination units per milliliter. Whole-
cell extracts (10 mg) were prepared at the indicated time points by using
RIPA buffer and incubating for 4 hr at 4C with 10 mg of either MAVS
(Millipore) or IgG antibody crosslinked to protein A/G Agarose beads (Pierce).
Beads were washed five times and proteins eluted by boiling for 3 min in SDS
sample lysis buffer.
Virus Infection
NY99 strain of WNV, CT2741, was used to infect A549 or MEFs at a moi of 1 or
3, mouse bone-marrow-derived macrophages at a moi of 5 unless specified.
Cantell strain of SeV (ATCC, #VR907) was added to cells at a concentration
of 40 hemagglutination units per milliliter, unless specified. DENV-2 (DENV
New Guinea C strain) was used at a moi = 1, unless specified.1068 Cell Reports 3, 1057–1070, April 25, 2013 ª2013 The AuthorsEnzyme-Linked Immunosorbent Assay, Type I IFN Bioavailability,
and Plaque-Forming Assays
ELISA of human or mouse TNF-a, IL-6 (R&D Systems), and IFN-b (PBL
Interferon Sources) in the cell culture medium was performed following the
manufacturers’ instructions. Type I IFNs in the cell culture medium were
quantified using a 2fGTH cell line stably expressing an ISRE-Luc reporter
(You et al., 2009). In brief, 200 ml of culture medium was incubated with
confluent 2fGTH-ISRE-Luc cells (24-well plate) for 6 hr. Cells were lysed in
passive lysis buffer and subjected to luciferase quantification (Promega). A
serial dilution of human IFN-b was included as standards. Viral titers from
the cell culture medium were determined by plaque-forming assays as
previously described (Wang et al., 2008; Cheng et al., 2010). Briefly, virus-
containing medium was serially diluted and then added to confluent Vero
cells. Plaques were visualized with Neutral Red (Sigma-Aldrich) 3 days
postinfection.
Statistical Analysis
Statistical significances were calculated with an unpaired two-tailed Student’s
t test using Prism 5 software (GraphPad).
For methods on plasmid construction and site-directed mutagenesis, lucif-
erase reporter assays, cell culture and transfection, quantitative RT-PCR,
immunoblotting analyses, immunofluorescence microscopy, and FRET anal-
ysis, please refer to Extended Experimental Procedures.
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